comparemela.com

Latest Breaking News On - Neilj campbell - Page 2 : comparemela.com

Marizyme, Inc. Strengthens Senior Management Team with Two Appointments: Roger Schaller EVP, Commercial Operations and Amy Chandler, EVP, Regulatory Affairs and Quality Management Systems

Share this article Share this article JUPITER, Fla., Feb. 1, 2021 /PRNewswire/  Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that it has added two life science industry veterans to its senior management team. Roger Schaller has been appointed Executive Vice President (EVP) of Commercial Operations, and Amy Chandler has been promoted to Executive Vice President (EVP) for Regulatory Affairs and Quality Management Systems. Mr. Schaller s extensive experience overseeing commercial operations, business development and successful product development will be a tremendous asset to Marizyme as we focus on advancing commercial operations and revenue generation in the year ahead, said Dr. Neil J. Campbell, Marizyme s CEO, President and Board Member. His expertise will be invaluable in building Marizym

Amy-chandler
Miriam-weber-miller
Ingrid-mezo
Roger-schaller
Neilj-campbell
Institute-of-textile-technology
Regulatory-affairs
Cepheid
Exchange-commission
Business-development-for-coyote-bioscience
Danaher-company
Business-development-at-promex-industries

Marizyme Announces the Use of DuraGraft® as the Standar

11 gennaio 2021 | 11.34 LETTURA: 5 minuti DuraGraft is a one-time intraoperative treatment used during vascular surgery to reduce the incidence of complications associated with graft failure JUPITER, Fla., Jan. 11, 2021 /PRNewswire/  Marizyme, Inc. (OTCQB: MRZM), a global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, today announced as of August 2020 the Vienna Heart Center North Floridsdorf of Vienna, Austria was the first clinic worldwide to use the company s flagship product, DuraGraft® as the standard-of-care for flushing and storage of the saphenous vein grafts from harvesting through grafting in Coronary Artery Bypass Grafting (CABG) patients.

Germany
Austria
Vienna
Wien
Floridsdorf
German
Ingrid-mezo
Maximilian-emmert
Martin-grabwenw
Miriam-miller
Neilj-campbell
Exchange-commission

Marizyme Announces the Use of DuraGraft® as the Standard-of-Care in [...]

11 gennaio 2021 11:38 Fonte: Adnkronos #salute-e-benessere DuraGraft is a one-time intraoperative treatment used during vascular surgery to reduce the incidence of complications associated with graft failure JUPITER, Fla., Jan. 11, 2021 /PRNewswire/  Marizyme, Inc. (OTCQB: MRZM), a global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, today announced as of August 2020 the Vienna Heart Center North Floridsdorf of Vienna, Austria was the first clinic worldwide to use the company s flagship product, DuraGraft® as the standard-of-care for flushing and storage of the saphenous vein grafts from harvesting through grafting in Coronary Artery Bypass Grafting (CABG) patients.

Germany
Austria
Vienna
Wien
Floridsdorf
German
Ingrid-mezo
Maximilian-emmert
Martin-grabwenw
Miriam-miller
Neilj-campbell
Exchange-commission

Marizyme, Inc. to Present at Biotech Showcase 2021 During the J.P. Morgan Healthcare Conference Biotech Showcase Digital, BIO @ JPM During J.P. Morgan Week 2021

Registration: https://informaconnect.com/biotech-showcase/registration-options/ During BIO @ JPM and Biotech Showcase Digital, Dr. Campbell will host virtual one-on-one meetings with registered investors and pharmaceutical companies to discuss Marizyme s pipeline of therapies that address urgent needs related to higher mortality and costs in the acute care space. The company s flagship product, DuraGraft , an intra-operative vascular graft storage solution that inhibits endothelial damage, leads to improved clinical outcomes by reducing the incidence of complications associated with vein graft failure in bypass surgery. DuraGraft is approved for use in the EU and several Asian countries but is not yet approved for use in the U.S. Marizyme is also focused on the development and marketing of products based on its clinically tested and previously patented protease-based therapeutic Krillase

Ingrid-mezo
Kostenloser-wertpapierhandel
Maureen-mcenroe
Miriam-miller
Neilj-campbell
Tiberend-strategic-advisors-inc
Exchange-commission
Prnewswire-marizyme-inc
Marizyme-inc
Chief-executive-officer
Biotech-showcase-digital
Biotech-showcase

Marizyme, Inc. to Present at Biotech Showcase 2021 During the J.P. Morgan Healthcare Conference Biotech Showcase Digital, BIO @ JPM During "J.P. Morgan Week 2021"

During BIO @ JPM and Biotech Showcase Digital, Dr. Campbell will host virtual one-on-one meetings with registered investors and pharmaceutical companies to discuss Marizyme s pipeline of therapies that address urgent needs related to higher mortality and costs in the acute care space. The company s flagship product, DuraGraft ®, an intra-operative vascular graft storage solution that inhibits endothelial damage, leads to improved clinical outcomes by reducing the incidence of complications associated with vein graft failure in bypass surgery. DuraGraft is approved for use in the EU and several Asian countries but is not yet approved for use in the U.S. Marizyme is also focused on the development and marketing of products based on its clinically tested and previously patented protease-based therapeutic Krillase

Ingrid-mezo
Maureen-mcenroe
Miriam-miller
Neilj-campbell
Exchange-commission
Marizyme-inc
Chief-executive-officer
Biotech-showcase-digital
Biotech-showcase
Myocardial-infarction
Repeat-revascularization
மவ்ரீன்-அம்கெந்ரொ

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.